Dendreon Corp fka DNDNQ

[walldiver]

<<Also note the bogus comparison of the benefit of GVAX shown in the phase-2 data vs. that of Taxotere shown in a much sicker population. The predicted survival time of patients before GVAX treatment was already better than the actual survival time of patients treated with Taxotere. Should that not tell them that the comparison was invalid due to wildly different patient populations? If this sort of sloppy thinking was a part of the trial design process...>>

It was a part of the trial design process. In the buildup to the trial initiation, and for awhile after that, CEGE trumpeted VITAL-1's 80% power to be stat sig if the median survival beat Taxotere's by 33%, and referred to the initial 18.9-month median survival figure for the ITT population of TAX327. This is the main reason that I'm skeptical of VITAL-1's chances for success.